Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells

Breast Cancer Research and Treatment

Volumn 134, Issue 2, 2012, Pages 495-510

  Debeb, Bisrat G ^a,b   Cohen, Evan N ^b   Boley, Kimberly ^b   Freiter, Erik M ^b   Li, Li ^a,b   Robertson, Fredika M ^b   Reuben, James M ^b   Cristofanilli, Massimo ^b,c   Buchholz, Thomas A ^a,b   Woodward, Wendy A ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Cancer stem cells; Inflammatory breast cancer; Notch; R04929097; Radiation

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CELL RENEWAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GENE TARGETING; HES1 GENE; HEY1 GENE; HEYL GENE; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; TUMOR GENE; TUMOR MICROENVIRONMENT;

ALDEHYDE DEHYDROGENASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BENZAZEPINES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BREAST NEOPLASMS; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NEOPLASTIC STEM CELLS; RADIATION-SENSITIZING AGENTS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR;

EID: 84868204453     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2075-8     Document Type: Article

References (62)

1. Li F, Tiede B, Massague J, Kang Y (2007) Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 17:3-14
2. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24 (-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98:1777-1785
3. Wicha MS, Liu S, Dontu G (2006) Cancer stem cells: an old idea-a paradigm shift. Cancer Res 66:1883-1890 (discussion 1895-1886)
4. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM (2007) WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104:618-623
5. Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10:R25
6. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672-679
7. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12:5615-5621
8. Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang X, Lodhi A, Krishnamurthy S, Hortobagyi GN et al (2011) Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+) CD24 (lo) cancer stem cell phenotype. Eur J Cancer 47 (10):1527-1536
9. -/lo cells in pleural effusion fluid of patients with metastatic breast cancer predicts for overall survival. Interv Oncol Soc J 1(1):4-10
10. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988
11. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567
12. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17:1253-1270
13. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60:351-375
14. Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH (2008) The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol 173:561-574
15. Xiao Y, Ye Y, Zou X, Jones S, Yearsley K, Shetuni B, Tellez J, Barsky SH (2011) The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction. Oncogene 30:287-300
16. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J et al (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69:1302-1313
17. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J et al (2010) Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 16:45-55
18. Kakarala M, Wicha MS (2008) Implications of the cancer stemcell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26:2813-2820
19. Radtke F, Schweisguth F, Pear W (2005) The Notch 'gospel'. EMBO Rep 6:1120-1125
20. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS (2004) Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6:R605-R615
21. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB (2010) Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 70:709-718
22. Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, Strack PR, Golde TE, Miele L, Foreman KE (2010) Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res 30:3853-3867
23. Korkaya H, Liu S, Wicha MS (2011) Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Investig 121:3804-3809
24. Patel SA, Dave MA, Murthy RG, Helmy KY, Rameshwar P (2011) Metastatic breast cancer cells in the bone marrow microenvironment: novel insights into oncoprotection. Oncol Rev 5:93-102
25. Shiao SL, Ganesan AP, Rugo HS, Coussens LM (2011) Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 25:2559-2572
26. Guise T (2010) Examining the metastatic niche: targeting the microenvironment. Semin Oncol 37(Suppl 2):S2-S14
27. Johansson M, Denardo DG, Coussens LM (2008) Polarized immune responses differentially regulate cancer development. Immunol Rev 222:145-154
28. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG et al (2011) Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 71:614-624
29. Storci G, Sansone P, Mari S, D'Uva G, Tavolari S, Guarnieri T, Taffurelli M, Ceccarelli C, Santini D, Chieco P et al (2010) TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol 225:682-691
30. Sun J, Krawczyk CJ, Pearce EJ (2008) Suppression of Th2 cell development by Notch ligands delta1 and delta4. J Immunol 180:1655-1661
31. Kubo M (2007) Notch: filling a hole in T helper 2 cell differentiation. Immunity 27:3-5
32. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA (2004) Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell 117:515-526
33. Pei J, Tang Z, Zang G, Yu Y (2010) Blockage of Notch1 signaling modulates the T-helper (Th) 1/Th2 cell balance in chronic hepatitis B patients. Hepatol Res 40:799-805
34. Ogawa H, Mukai K, Kawano Y, Minegishi Y, Karasuyama H (2012) Th2-inducing cytokines IL-4 and IL-33 synergistically elicit the expression of transmembrane TNF-alpha on macrophages through the autocrine action of IL-6. Biochem Biophys Res Commun 420:114-118
35. Amsen D, Spilianakis CG, Flavell RA (2009) How are T (H) 1 and T (H) 2 effector cells made? Curr Opin Immunol 21:153-160
36. Yuan JS, Kousis PC, Suliman S, Visan I, Guidos CJ (2010) Functions of notch signaling in the immune system: consensus and controversies. Annu Rev Immunol 28:343-365
37. Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W, Hilton H et al (2009) Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 69:7672-7680
38. He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X, Cai J, Higgins B, Kolinsky K, Rizzo C et al (2011) High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the gamma-secretase inhibitor, RO4929097. Mol Oncol 5(3):292-301
39. Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA (2010) Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 76:889-895
40. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH (2006) Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 106:2437-2444
41. Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, Reuben JM (2005) Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19:1905-1911
42. Villiger PM, Cronin MT, Amenomori T, Wachsman W, Lotz M (1991) IL-6 production by human T lymphocytes. Expression in HTLV-1-infected but not in normal T cells. J Immunol 146:550-559
43. Chen JQ, Russo J (2009) ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta 1796:162-175
44. Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar. BG, Klinakis A, Lukyanov Y, Tseng JC, Sen F et al (2009) CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 459:1000-1004
45. Rao GS, Murray S, Ethier SP (2000) Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 48:1519-1528
46. Woodward WA, Debeb BG, Xu W, Buchholz TA (2010) Overcoming radiation resistance in inflammatory breast cancer. Cancer 116:2840-2845
47. Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, Lindeman GJ, Visvader JE (2008) Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 3:429-441
48. Kwon C, Cheng P, King IN, Andersen P, Shenje L, Nigam V, Srivastava D (2011) Notch post-translationally regulates betacatenin protein in stem and progenitor cells. Nat Cell Biol 13(10):1244-1251
49. Kwon C, Qian L, Cheng P, Nigam V, Arnold J, Srivastava D (2009) A regulatory pathway involving Notch1/beta-catenin/Isl1 determines cardiac progenitor cell fate. Nat Cell Biol 11:951-957
50. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB et al (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117:3988-4002
51. Levina V, Marrangoni AM, De Marco R, Gorelik E, Lokshin AE (2008) Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE 3:e3077
52. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103-113
53. Efimova EV, Liang H, Pitroda SP, Labay E, Darga TE, Levina V, Lokshin A, Roizman B, Weichselbaum RR, Khodarev NN (2009) Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol 85:421-431
54. Iliopoulos D, Hirsch HA, Wang G, Struhl K (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 108:1397-1402
55. Cohen EN, Lee BN, Gao H, Andreopoulou E, Jackson SA, Parker CA, Tin S, Li Y-D, Galland MM, Cristofanilli M, Reuben JM (2009) Soluble factors and circulating tumor cells in inflammatory breast cancer. Cancer Res 69(24 Suppl):Abstract nr 2135
56. Van Laere S, Van Der Auwera I, Van Den Eynden GG, Fox SB, Bianchi F, Harris AL, Van Dam P, Van Marck EA, Vermeulen PB, Dirix LY (2005) Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 93:237-246
57. Van Laere SJ, Van Der Auwera I, Van Den Eynden GG, Elst HJ, Weyler J, Harris AL, Van Dam P, Van Marck EA, Vermeulen PB, Dirix LY (2006) Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res 12:3249-3256
58. Murugan V, Peck MJ (2009) Signal transduction pathways linking the activation of alveolar macrophages with the recruitment of neutrophils to lungs in chronic obstructive pulmonary disease. Exp Lung Res 35:439-485
59. Strieter RM, Kunkel SL, Bone RC (1993) Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 21:S447-S463
60. Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J, Hong D et al (2011) Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon alpha for patients with solid tumors. J Cancer 2:81-89
61. Amsen D, Antov A, Jankovic D, Sher A, Radtke F, Souabni A, Busslinger M, McCright B, Gridley T, Flavell RA (2007) Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity 27:89-99
62. Minter LM, Turley DM, Das P, Shin HM, Joshi I, Lawlor RG, Cho OH, Palaga T, Gottipati S, Telfer JC et al (2005) Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol 6:680-688